News

Ebola virus hides out in brain

Monkeys treated with monoclonal antibodies fully recovered, but infection recurred
Kevin Zeng
By Kevin Zeng
April 16, 2022

The Ebola virus can hide in the brains of monkeys that have recovered after medical treatment without causing symptoms and lead to recurrent infections, according to a study by a team I led that was published in the journal Science Translational Medicine.

Ebola is one of the deadliest infectious disease threats known to humankind, with an average fatality rate of about 50%. Ebola is known for a high level of viral persistence, meaning the virus remains lurking in the body even after a patient has recovered. But where this hiding place is remains largely unknown.

This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).
National Institute of Allergy and Infectious Diseases/Flickr, CC BY-SA
This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).

In 2021, there were three Ebola outbreaks in Africa, all linked to previously infected survivors. Ebola also reemerged in Guinea that same year, linked to a survivor of the 2013-2016 Ebola outbreak.

Email Twitter19 Facebook902 LinkedIn Print  The Research Brief is a short take about interesting academic work. The big idea  The Ebola virus can hide in the brains of monkeys that have recovered after medical treatment without causing symptoms and lead to recurrent infections, according to a study by a team I led that was published in the journal Science Translational Medicine.  Ebola is one of the deadliest infectious disease threats known to humankind, with an average fatality rate of about 50%25. Ebola is known for a high level of viral persistence, meaning the virus remains lurking in the body even after a patient has recovered. But where this hiding place is remains largely unknown.  In 2021, there were three Ebola outbreaks in Africa, all linked to previously infected survivors. Ebola also reemerged in Guinea that same year, linked to a survivor of the 2013-2016 Ebola outbreak. Don’t let yourself be misled. Understand issues with help from experts A laboratory technician in full Personal protective equipment pipettes samples under a lab hood. The researchers conducted their study in a Biosafety Level 4 lab, the highest level of biocontainment required to safely study hazardous pathogens like Ebola.
John W. Braun, USAMRIID, CC BY-NC-ND
The researchers conducted their study in a Biosafety Level 4 lab, the highest level of biocontainment required to safely study hazardous pathogens like Ebola.

We wanted to better understand where the Ebola virus “hides” in the body of survivors and what triggers recurrent infections. So we examined 36 rhesus monkeys that had been treated for Ebola with monoclonal antibody therapy, a type of treatment that helps the immune system mount an attack against an infection. These monkeys were deemed fully recovered with no symptoms of infection or detectable virus in their blood.

When we looked more closely at the tissues of different organs under a microscope, however, we found that about 20% of recovered monkeys still had visible Ebola virus located exclusively in the ventricular system of the brain. This brain region produces, circulates and stores cerebrospinal fluid, which protects, supplies nutrients to and removes waste products from the brain.

Importantly, despite being asymptomatic at the start of our study, two of the monkeys we observed developed Ebola symptoms before dying at 30 and 39 days after their initial infection, respectively. Our findings suggest that the Ebola virus can hide dormant in the brains of survivors even after treatment, and the virus can reactivate and cause fatal infections later on.

This image shows the brain ventricular system of a rhesus monkey that survived Ebola virus infection, where brown indicates viral persistence.
Kevin Zeng, CC BY-NC-ND
This image shows the brain ventricular system of a rhesus monkey that survived Ebola virus infection, where brown indicates viral persistence.

Why it matters

Treatment with monoclonal antibodies is the current standard of care for Ebola. But recurrent infections can occur even after apparently successful treatment, and patients can inadvertently transmit the virus and cause new outbreaks.

Our study underscores the importance of careful long-term medical follow-up of successfully treated Ebola survivors to counter the individual and public health cost of recurrent disease. This follow-up, however, will need to be conducted in a way that does not further stigmatize survivors of the disease.

What still isn’t known

We still don’t know why the Ebola virus persists in the brain and causes recurrent infections. It is also unclear whether this persistence might be related to monoclonal antibody treatments, and whether other types of therapies, such as antivirals, might produce a different effect. Researchers are still looking into what triggers relapses and whether there might be other parts of the body that may act as reservoirs.

What’s next

Our work highlights the need to more deeply investigate why the Ebola virus persists in the brain. Because the brain is less accessible to monoclonal antibodies, treatments combining both monoclonal antibodies and antiviral drugs may help prevent and clear persistent Ebola infection and related disease in the brain. Analyzing viral persistence at the molecular level may provide more insight.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Kevin Zeng
Kevin Zeng

Kevin Zeng is a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

From the journals: JLR
Journal News

From the journals: JLR

Sept. 30, 2022

A new site-specific cholesterol control option and a better way to assess vitamin D status in critical care. Read about papers on these topics recently published in the Journal of Lipid Research.

Living in a bubble
Annual Meeting

Living in a bubble

Sept. 29, 2022

This symposium, Protein Machines and Disorder, will be part of #DiscoverBMB 2023.

Keep your friends close and your RNAs closer
Annual Meeting

Keep your friends close and your RNAs closer

Sept. 29, 2022

This symposium, Regulation of RNA, will be part of #DiscoverBMB 2023.

A membrane ATPase without transporter activity
Journal News

A membrane ATPase without transporter activity

Sept. 28, 2022

A classic article in the Journal of Biological Chemistry reflects on Guido Guidotti’s laboratory and the search for CD39.

The era of “smart” organelles
Annual Meeting

The era of “smart” organelles

Sept. 28, 2022

This symposium, Organelles, Mechanisms and Phase Properties of Cellular Quality Control, will be part of #DiscoverBMB 2023.

Lipids, lipids everywhere!
Annual Meeting

Lipids, lipids everywhere!

Sept. 27, 2022

This symposium, Lipid Dynamics and Signals in Membrane and Protein Structure, will be part of #DiscoverBMB 2023.